Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib maintenance after HCT for acute leukemia
NCT03267186Phase 2Completed
- Start
- Sep 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), Acute Biphenotypic Leukemia (BAL). Started Sep 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)Acute Biphenotypic Leukemia (BAL)
Beyond the preview
Go deeper on NCT03267186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267186.